SCHEMBL4674906

SCHEMBL4674906

COc1ccccc1Oc1occc1C(=O)C=C(O)c1nc[nH]n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.40
CYP1B1 Q16678 2/20 0.40
ABCB1 P08183 1/20 0.40
LMNA P02545 3/20 0.38
HTT P42858 1/20 0.37
POLB P06746 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KCNA3 P22001 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
NPC1 O15118 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675173 0.88 RAB9A (0.33) CYP1A1CYP1B1ABCB1HTTPOLB
SCHEMBL4676663 0.86 CYP1A1 (0.36) CYP1A1CYP1B1ABCB1LMNAHTT
SCHEMBL4674086 0.85 CYP1A1 (0.36) CYP1A1CYP1B1ABCB1LMNAPOLB
SCHEMBL4674286 0.85 RXRA (0.33) CYP1A1CYP1B1ABCB1
SCHEMBL4670767 0.84 HTT (0.38) CYP1A1CYP1B1ABCB1LMNAHTT
SCHEMBL4674895 0.84 KDM4E (0.40) CYP1A1CYP1B1ABCB1LMNAHTT
SCHEMBL4675284 0.82 HTT (0.40) CYP1A1CYP1B1ABCB1LMNAHTT
SCHEMBL4673836 0.81 CYP1A1 (0.36) CYP1A1CYP1B1ABCB1LMNAHTT
SCHEMBL4675705 0.81 NPC1 (0.41) CYP1A1CYP1B1ABCB1LMNAHTT
SCHEMBL4676198 0.79 MAPT (0.37) CYP1A1CYP1B1ABCB1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CYP1A1 45/4885CYP1B1 31/4885ABCB1 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.